WO2022098324A1 - A new pharmaceutical composition produced by lyophylisation method containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide active ingredient or its sodium salt - Google Patents
A new pharmaceutical composition produced by lyophylisation method containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide active ingredient or its sodium salt Download PDFInfo
- Publication number
- WO2022098324A1 WO2022098324A1 PCT/TR2021/050149 TR2021050149W WO2022098324A1 WO 2022098324 A1 WO2022098324 A1 WO 2022098324A1 TR 2021050149 W TR2021050149 W TR 2021050149W WO 2022098324 A1 WO2022098324 A1 WO 2022098324A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pyrazinecarboxamide
- fluoro
- hydroxy
- sodium
- sodium salt
- Prior art date
Links
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 17
- 159000000000 sodium salts Chemical class 0.000 title claims abstract description 16
- 238000000034 method Methods 0.000 title claims abstract description 9
- 239000004480 active ingredient Substances 0.000 title abstract description 18
- 230000003612 virological effect Effects 0.000 claims abstract description 6
- 201000010099 disease Diseases 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 5
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 4
- 229940042126 oral powder Drugs 0.000 claims abstract 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 36
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 24
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 16
- 239000004376 Sucralose Substances 0.000 claims description 14
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 14
- 235000019408 sucralose Nutrition 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 12
- 239000008176 lyophilized powder Substances 0.000 claims description 11
- 238000010790 dilution Methods 0.000 claims description 8
- 239000012895 dilution Substances 0.000 claims description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 7
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- PRBFTAJMQYDJMU-UHFFFAOYSA-M sodium (5-fluoro-2-oxo-1H-pyrazine-3-carbonyl)azanide Chemical compound [Na+].FC1=CN=C(C(=N1)C(=O)[NH-])O PRBFTAJMQYDJMU-UHFFFAOYSA-M 0.000 claims description 4
- 238000012371 Aseptic Filling Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000007916 tablet composition Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 235000011121 sodium hydroxide Nutrition 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229950008454 favipiravir Drugs 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical class NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- -1 ribofuranosyl triphosphate derivative Chemical class 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Definitions
- the present invention relates to a new pharmaceutical composition produced by lyophylisation method containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide active ingredient or its sodium salt
- the present invention particularly relates to a new pharmaceutical composition in the form of lyophilized powder for diluted use, produced by the lyophylisation method, containing 6- fluoro-3-hydroxy-2-pyrazinecarboxamide active ingredient or sodium salt, for the therapeutic treatment of viral diseases and production method thereof.
- 6-fluoro-3-hydroxy-2-pyrazinecarboxamide active ingredient that is used in tablet dosage form for the treatment of viral diseases is a pyrazine carboxamide derivative with activity against RNA viruses.
- This active ingredient is transformed into the ribofuranosyl triphosphate derivative by host enzymes and selectively inhibits viral RNA-dependent RNA polymerase.
- each tablet contains microcrystalline cellulose, solubilizer except Pavipavir active ingredient; disintegrating, lubricant and lubricating agents.
- the existing tablet formulations contain many excipients besides the active ingredient.
- tablet formulations have the problem of low dissolution rate. Therefore, the absorption of the active ingredient by the human body and the success of the treatment are significantly affected in a negative manner.
- the present invention relates to a novel pharmaceutical composition containing the 6- fluoro-3-hydroxy-2-pyrazinecarboxamide active ingredient or pharmaceutically acceptable sodium salt, that fulfills the above-mentioned requirements, eliminates all disadvantages, and brings some additional advantages.
- the main aim of the invention is to provide an effective treatment in viral diseases without causing any adverse effects with the lyophilized powder formulation having high purity.
- An aim of the invention is to provide a new pharmaceutical composition-that exhibits high solubility, is stable, is for use by dilution from the final product, and provides ease of use and safety.
- Another aim of the invention is to provide a novel pharmaceutical composition that provides effective solubility and stability as well as taste suitable for diluted use with the lyophilized powder dosage form, which is presented by using the preferred excipients in specific ratios, in addition to the active ingredient.
- the invention is a pharmaceutical composition in the form of lyophilized powder form for use by dilution, it comprises 6-fluoro-3-hydroxy- 2-pyrazinecarboxamide or pharmaceutically acceptable sodium salt as active ingredient, and individuals or combinations selected from sodium hydroxide, sodium bicarbonate, sodium carbonate, sucralose as excipients.
- the invention is method of preparing pharmaceutical composition in the form of lyophilized powder form for use by dilution, it comprises the processes of preparing a homogenized aqueous solution by using 6-fluoro- 3-hydroxy-2-pyrazinecarboxamide or sodium salt and sodium hydroxide, sodium bicarbonate or sodium carbonate, preferably by adding sucralose, and applying sterilization, aseptic filling, and lyophylisation to the prepared solution.
- inventive pharmaceutical composition and the production method thereof is described only for clarifying the subject matter in a manner such that no limiting effect is created.
- 6-fluoro-3-hydroxy-2-pyrazinecarboxamide is a modified pyrazine analog approved for therapeutic use in viral cases.
- 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or pharmaceutically acceptable sodium salt are used as active ingredient, and sucralose, sodium hydroxide, sodium bicarbonate, sodium bicarbonate or sodium carbonate are used as excipients. It is provided in the form of lyophilized powder, which will be prepared and applied suitably after dilution for use. Sucralose is preferred as a sweetener that provides potability of the oral solution to be prepared. Sodium hydroxide, sodium bicarbonate or sodium carbonate makes contribution to the solubility of 6-fluoro-3- hydroxy-2-pyrazinecarboxamide by adjusting the pH of the solution in the solution to be prepared. Table.1 : Content of a preferred embodiment of the invention s.a.: sufficient amount
- Table. 2 Content of a preferred embodiment of the invention
- the invention is essentially a pharmaceutical composition in the form of lyophilized powder form for use by dilution, it comprises 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or pharmaceutically acceptable sodium salt as active ingredient, and individuals or combinations selected from sodium hydroxide, sodium bicarbonate, sodium carbonate, sucralose as excipients.
- the pharmaceutical composition contains minimum 86% ratio of 6-fluoro-3-hydroxy-2-pyrazinecarboxamide by weight.
- the pharmaceutical composition contains minimum 99,6% ratio of 6-fluoro-3-hydroxy-2-pyrazinecarboxamide sodium salt by weight. According to an embodiment of the invention, the composition also contains individuals or combinations selected from sodium hydroxide, sodium bicarbonate, sodium carbonate in sufficient amount.
- the pharmaceutical composition preferably contains a maximum of 1% ratio of sucralose by weight.
- a preferred embodiment of the invention contains 86% ratio of 6-fluoro-3-hydroxy-2- pyrazinecarboxamide by weight; 1% ratio of sucralose by weight; sufficient amount of sodium hydroxide, sodium bicarbonate or sodium carbonate.
- Another preferred embodiment of the invention contains 99,6% ratio of 6-fluoro-3-hydroxy- 2-pyrazinecarboxamide sodium salt by weight; %0,4 ratio of sucralose by weight.
- composition production method in lyophilized powder form for preparing the inventive oral solution initiates with the preparation of an aqueous solution by mixing the raw materials given in Table 1 in the specified amounts at room temperature.
- Homogenized aqueous solution is prepared by using 6-fluoro-3-hydroxy-2- pyrazinecarboxamide or pharmaceutically acceptable sodium salt and sodium hydroxide, sodium bicarbonate or sodium carbonate, preferably by adding sucralose.
- Sterile filtration is applied to the prepared solution.
- Aseptic filling of the sterilized solution is performed and lyophilization is applied so as to obtain the final product in the form of lyophilized powder containing the active ingredient of 6-fluoro-3-hydroxy-2-pyrazinecarboxamide.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a new pharmaceutical composition in the form of lyophilized oral powder form for diluted use, produced by the lyophylisation method, containing the active ingredient 6-fluoro-3-hydroxy-2-pyrazinecarboxamide active ingredient or sodium salt, for the therapeutic treatment of viral diseases and production method thereof.
Description
A new pharmaceutical composition produced by lyophylisation method containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide active ingredient or its sodium salt
Field of the Invention
The present invention relates to a new pharmaceutical composition produced by lyophylisation method containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide active ingredient or its sodium salt
The present invention particularly relates to a new pharmaceutical composition in the form of lyophilized powder for diluted use, produced by the lyophylisation method, containing 6- fluoro-3-hydroxy-2-pyrazinecarboxamide active ingredient or sodium salt, for the therapeutic treatment of viral diseases and production method thereof.
State of the Art
Today, 6-fluoro-3-hydroxy-2-pyrazinecarboxamide active ingredient that is used in tablet dosage form for the treatment of viral diseases is a pyrazine carboxamide derivative with activity against RNA viruses. This active ingredient is transformed into the ribofuranosyl triphosphate derivative by host enzymes and selectively inhibits viral RNA-dependent RNA polymerase.
Formula I
In the patent application numbered KR20110126699A, tablet formulation that is easily sized, resistant to film-coating, packaging and shipping contains a high content of 6-fluoro- 3-hydroxy-2-pyrazinecarboxamide or its salts is disclosed. In the patent numbered CN105687152B, a rapid release Favipiravir tablet formulation is disclosed. Here, each
tablet contains microcrystalline cellulose, solubilizer except Pavipavir active ingredient; disintegrating, lubricant and lubricating agents.
The existing tablet formulations contain many excipients besides the active ingredient. In addition to this, tablet formulations have the problem of low dissolution rate. Therefore, the absorption of the active ingredient by the human body and the success of the treatment are significantly affected in a negative manner.
For this reason, a formulation that allows the oral administration of the 6-fluoro-3-hydroxy- 2-pyrazinecarboxamide active ingredient, eliminates dissolution, release and absorption problems, and does not exhibit the side effects of multiple ingredients of other pharmaceutical forms and ready-to-use.
As a result, due to the abovementioned disadvantages and the insufficiency of the current solutions regarding the subject matter, a development is required to be made in the relevant technical field.
Brief Description of the Invention
The present invention relates to a novel pharmaceutical composition containing the 6- fluoro-3-hydroxy-2-pyrazinecarboxamide active ingredient or pharmaceutically acceptable sodium salt, that fulfills the above-mentioned requirements, eliminates all disadvantages, and brings some additional advantages.
The main aim of the invention is to provide an effective treatment in viral diseases without causing any adverse effects with the lyophilized powder formulation having high purity.
An aim of the invention is to provide a new pharmaceutical composition-that exhibits high solubility, is stable, is for use by dilution from the final product, and provides ease of use and safety.
Another aim of the invention is to provide a novel pharmaceutical composition that provides effective solubility and stability as well as taste suitable for diluted use with the lyophilized powder dosage form, which is presented by using the preferred excipients in specific ratios, in addition to the active ingredient.
In order to fulfill the abovementioned aims, the invention is a pharmaceutical composition in the form of lyophilized powder form for use by dilution, it comprises 6-fluoro-3-hydroxy-
2-pyrazinecarboxamide or pharmaceutically acceptable sodium salt as active ingredient, and individuals or combinations selected from sodium hydroxide, sodium bicarbonate, sodium carbonate, sucralose as excipients.
In order to fulfill the abovementioned aims, the invention is method of preparing pharmaceutical composition in the form of lyophilized powder form for use by dilution, it comprises the processes of preparing a homogenized aqueous solution by using 6-fluoro- 3-hydroxy-2-pyrazinecarboxamide or sodium salt and sodium hydroxide, sodium bicarbonate or sodium carbonate, preferably by adding sucralose, and applying sterilization, aseptic filling, and lyophylisation to the prepared solution.
The structural and characteristic features of the present invention will be understood clearly by the following detailed description and therefore the evaluation shall be made by taking the detailed description into consideration.
Detailed Description of the Invention
In this detailed description, the inventive pharmaceutical composition and the production method thereof is described only for clarifying the subject matter in a manner such that no limiting effect is created.
6-fluoro-3-hydroxy-2-pyrazinecarboxamide is a modified pyrazine analog approved for therapeutic use in viral cases.
In the inventive composition, 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or pharmaceutically acceptable sodium salt are used as active ingredient, and sucralose, sodium hydroxide, sodium bicarbonate, sodium bicarbonate or sodium carbonate are used as excipients. It is provided in the form of lyophilized powder, which will be prepared and applied suitably after dilution for use. Sucralose is preferred as a sweetener that provides potability of the oral solution to be prepared. Sodium hydroxide, sodium bicarbonate or sodium carbonate makes contribution to the solubility of 6-fluoro-3- hydroxy-2-pyrazinecarboxamide by adjusting the pH of the solution in the solution to be prepared.
Table.1 : Content of a preferred embodiment of the invention
s.a.: sufficient amount
Table. 2: Content of a preferred embodiment of the invention
The invention is essentially a pharmaceutical composition in the form of lyophilized powder form for use by dilution, it comprises 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or pharmaceutically acceptable sodium salt as active ingredient, and individuals or combinations selected from sodium hydroxide, sodium bicarbonate, sodium carbonate, sucralose as excipients.
According to an embodiment of the invention, the pharmaceutical composition contains minimum 86% ratio of 6-fluoro-3-hydroxy-2-pyrazinecarboxamide by weight.
According to an embodiment of the invention, the pharmaceutical composition contains minimum 99,6% ratio of 6-fluoro-3-hydroxy-2-pyrazinecarboxamide sodium salt by weight.
According to an embodiment of the invention, the composition also contains individuals or combinations selected from sodium hydroxide, sodium bicarbonate, sodium carbonate in sufficient amount.
According to an embodiment of the invention, the pharmaceutical composition preferably contains a maximum of 1% ratio of sucralose by weight.
A preferred embodiment of the invention contains 86% ratio of 6-fluoro-3-hydroxy-2- pyrazinecarboxamide by weight; 1% ratio of sucralose by weight; sufficient amount of sodium hydroxide, sodium bicarbonate or sodium carbonate.
Another preferred embodiment of the invention contains 99,6% ratio of 6-fluoro-3-hydroxy- 2-pyrazinecarboxamide sodium salt by weight; %0,4 ratio of sucralose by weight.
Pharmaceutical composition production method in lyophilized powder form for preparing the inventive oral solution; initiates with the preparation of an aqueous solution by mixing the raw materials given in Table 1 in the specified amounts at room temperature. Homogenized aqueous solution is prepared by using 6-fluoro-3-hydroxy-2- pyrazinecarboxamide or pharmaceutically acceptable sodium salt and sodium hydroxide, sodium bicarbonate or sodium carbonate, preferably by adding sucralose. Sterile filtration is applied to the prepared solution. Aseptic filling of the sterilized solution is performed and lyophilization is applied so as to obtain the final product in the form of lyophilized powder containing the active ingredient of 6-fluoro-3-hydroxy-2-pyrazinecarboxamide. Dosages of 600 mg of 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or 1600 mg of 6-fluoro-3-hydroxy-2- pyrazinecarboxamide or equivalent amounts of sodium salt is packaged as lyophilized powder and is placed on the market as a generic human drug for use by dilution.
Claims
1. A pharmaceutical composition in the form of lyophilized oral powder that can be used after dilution, characterized by comprising; 6-fluoro-3-hydroxy-2 pyrazinecarboxamide or its sodium salt.
2. Composition according to claim 1 , characterized by comprising; a minimum of 86% ratio of 6-fluoro-3-hydroxy-2-pyrazinecarboxamide by weight.
3. Composition according to claim 1 , characterized by comprising; a minimum of 99,6% ratio of 6-fluoro-3-hydroxy-2-pyrazinecarboxamide sodium salt by weight.
4. Composition according to claim 1 , characterized by comprising; individuals or combinations selected from sodium hydroxide, sodium bicarbonate, sodium carbonate.
5. Composition according to claim 4, characterized characterized by comprising; sufficient amount of sodium hydroxide, sodium bicarbonate or sodium carbonate.
6. Composition according to claim 1 , characterized by comprising; sucralose.
7. Composition according to claim 6, characterized by comprising; maximum 1% ratio of sucralose by weight.
8. Composition according to claim 1 , characterized by comprising; 86% ratio of 6- fluoro-3-hydroxy-2-pyrazinecarboxamide by weight; 1% ratio of sucralose by weight; sufficient amount of sodium hydroxide, sodium bicarbonate or sodium carbonate.
9. Composition according to claim 1 , characterized by comprising; 99,6% ratio of 6- fluoro-3-hydroxy-2-pyrazinecarboxamide sodium salt by weight; %0,4 ratio of sucralose by weight.
10. Composition according to claim 1 , characterized in that; it is presented in the lyophilized oral powder form that contains sodium salt in dosages of 600 mg of 6- fluoro-3-hydroxy-2-pyrazinecarboxamide or 1600 mg of 6-fluoro-3-hydroxy-2- pyrazinecarboxamide or equivalent amounts of their sodium salt for therapeutic treatment of viral diseases.
11. A method of preparing pharmaceutical composition in the form of lyophilized powder for use by dilution, characterized by comprising of the following processes of
preparing a homogenized aqueous solution by using 6-fluoro-3-hydroxy-2- pyrazinecarboxamide or sodium salt and sodium hydroxide, sodium bicarbonate or sodium carbonate, preferably by adding sucralose, and applying sterilization, aseptic filling, and lyophylisation to the prepared solution.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2020/17792 | 2020-11-06 | ||
| TR2020/17792A TR202017792A2 (en) | 2020-11-06 | 2020-11-06 | A new pharmaceutical composition produced by lyophilization technique containing the active ingredient of 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or its sodium salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022098324A1 true WO2022098324A1 (en) | 2022-05-12 |
Family
ID=75575978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2021/050149 WO2022098324A1 (en) | 2020-11-06 | 2021-02-17 | A new pharmaceutical composition produced by lyophylisation method containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide active ingredient or its sodium salt |
Country Status (2)
| Country | Link |
|---|---|
| TR (1) | TR202017792A2 (en) |
| WO (1) | WO2022098324A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2623498A1 (en) * | 2010-09-30 | 2013-08-07 | Toyama Chemical Co., Ltd. | Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide |
| CN111228226A (en) * | 2020-03-06 | 2020-06-05 | 瑞阳制药有限公司 | Freeze-dried preparation of pyrrosia faberi for injection and preparation method thereof |
| EP3733182A1 (en) * | 2017-12-28 | 2020-11-04 | FUJIFILM Toyama Chemical Co., Ltd. | Method for producing freeze-dried formulation |
-
2020
- 2020-11-06 TR TR2020/17792A patent/TR202017792A2/en unknown
-
2021
- 2021-02-17 WO PCT/TR2021/050149 patent/WO2022098324A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2623498A1 (en) * | 2010-09-30 | 2013-08-07 | Toyama Chemical Co., Ltd. | Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide |
| EP3733182A1 (en) * | 2017-12-28 | 2020-11-04 | FUJIFILM Toyama Chemical Co., Ltd. | Method for producing freeze-dried formulation |
| CN111228226A (en) * | 2020-03-06 | 2020-06-05 | 瑞阳制药有限公司 | Freeze-dried preparation of pyrrosia faberi for injection and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| LI JIAWEN, ZHANG CHI, WU ZHAO, WANG GUIQIANG, ZHAO HONG: "The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial", TRIALS, vol. 21, no. 1, 1 December 2020 (2020-12-01), XP055788499, DOI: 10.1186/s13063-020-04430-y * |
| TANI HIDEKI, KOMENO TAKASHI, FUKUMA AIKO, FUKUSHI SHUETSU, TANIGUCHI SATOSHI, SHIMOJIMA MASAYUKI, UDA AKIHIKO, MORIKAWA SHIGERU, N: "Therapeutic effects of favipiravir against severe fever with thrombocytopenia syndrome virus infection in a lethal mouse model: Dose-efficacy studies upon oral administration", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, vol. 13, no. 10, 26 October 2018 (2018-10-26), US , pages e0206416-1 - e0206416-10, XP055939168, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0206416 * |
Also Published As
| Publication number | Publication date |
|---|---|
| TR202017792A2 (en) | 2021-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090191288A1 (en) | Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases | |
| TW201223529A (en) | Pharmaceutical compositions | |
| RU2401109C2 (en) | Tablet-form slow-release preparation for vertigo | |
| KR20100093105A (en) | Dispersible tablet | |
| KR20030097892A (en) | Drug preparations | |
| TWI495469B (en) | Improved pharmaceutical compositions containing a fluoroquinolone antibiotic drug | |
| HU229264B1 (en) | Reconstitutable parenteral composition containing a cox-2 inhibitor | |
| US20170258861A1 (en) | Treatment of Herpes, Pseudomonas, Staph, and Hepatitis | |
| JPH1160505A (en) | Antiseptic composition | |
| EP3360547B1 (en) | Bactericidal pharmaceutical composition comprising ibuprofen | |
| WO2014010656A1 (en) | Superior blood alcohol concentration reduction accelerating agent | |
| JP3264937B2 (en) | Pharmaceutical composition | |
| JP6088151B2 (en) | Pharmaceutical composition | |
| JP2008528572A (en) | Injectable preparation of diclofenac and its pharmaceutically acceptable salts | |
| PT90356B (en) | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS CONTAINING PENTAMIDINE AQUEOUS SOLUTIONS | |
| RU2363462C2 (en) | Pharmaceutical composition containing 5-methyl-2-(2′-chloro-6′- fluoroaniline)phenylacetic acid | |
| WO2022098324A1 (en) | A new pharmaceutical composition produced by lyophylisation method containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide active ingredient or its sodium salt | |
| RU2536958C2 (en) | Drug preparation for treating cataract and method for preparing it (versions) | |
| AU2018332212B2 (en) | Topical formulations of chloroprocaine | |
| JP5823131B2 (en) | A composition containing windproof tsushosan | |
| EP3678498B1 (en) | Composition for calcium supplementation | |
| KR102498401B1 (en) | Eye drops composition for treating and preventing cataract | |
| JP2003342186A (en) | Oral liquid formulation composition for rhinitis | |
| US20230082870A1 (en) | Composition for calcium supplementation | |
| RU2571279C1 (en) | Pharmaceutical composition containing azapentacene (versions) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21889742 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 21889742 Country of ref document: EP Kind code of ref document: A1 |